


Atty. Docket No.: PG3416US2

**REMARKS**

Claims 1-12 are originally filed in the application. Claims 4-12 are amended herein. Claims 13-36 are added. Accordingly, Claims 1-36 are presented for Examination. Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



John L. Lemanowicz  
Attorney for Applicants  
Registration No. 37,380

Date: 21 January, 2003  
Glaxo SmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8247

Atty. Docket No.: PG3416US2

**Amended Claims – Marked Up Version**

4. (Amended) A method as claimed in claim [1] 3, wherein the susceptible cancer is a susceptible breast cancer.
5. (Amended) A method as claimed in claim [1] 3, wherein the susceptible cancer is a susceptible non-small cell lung cancer.
6. (Amended) A method as claimed in claim [1] 3, wherein the susceptible cancer is a susceptible ovarian cancer.
7. (Amended) A method as claimed in claim [1] 3, wherein the susceptible cancer is a susceptible stomach cancer.
8. (Amended) A method as claimed in claim [1] 3, wherein the susceptible cancer is a susceptible pancreatic cancer.
9. (Amended) A method as claimed in claim [1] 3, wherein the susceptible cancer is a susceptible head and neck cancer.
10. (Amended) A method as claimed in claim [1] 3, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR.
11. (Amended) A method as claimed in claim [1] 3, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of erbB-2.
12. (Amended) A method as claimed in claim [1] 3, wherein the susceptible cancer is a susceptible cancer characterized by expression or over-expression of EGFR and erbB-2.

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

### Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on 1/21/03  
Date

Allyson K. Jacobs  
Signature

Allyson K. Jacobs  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.